IR-Center Handelsblatt
Unternehmenssuche:

Sangui BioTech International Inc.

News Detail

DGAP-News News vom 25.07.2018

Sangui BioTech International Inc.: Revenues of USD 74,000 in fiscal year 2018; Introduction on the market of Granulox in Southeast Asia is proceeding according to plan; Foundation of Sangui Know-How - und Patentverwertungsgesellschaft mbH & Co. KG

DGAP-News: Sangui BioTech International Inc. / Key word(s): Preliminary Results

25.07.2018 / 11:07
The issuer is solely responsible for the content of this announcement.



 

Sangui BioTech:


- Revenues of USD 74,000 in fiscal year 2018;
- Introduction on the market of Granulox in Southeast Asia is proceeding according to plan;

- Foundation of Sangui Know-How - und Patentverwertungsgesellschaft mbH & Co. KG.

Witten, July 25, 2017

According to preliminary unaudited figures, Sangui BioTech International Inc. achieved revenues in the amount of approximately USD 74,000 from license fees in the course of its financial year 2018 (as of June 30, 2018). Due to increased revenues of the wound spray Granulox the resulting licensing income could be increased by 9% compared to the previous year. While revenues in the first half of the year were significantly higher than in the same period of the previous year, revenues in the second half of the year had to decline. The reason for this development was the fact that prior to the participation of Mölnlycke Health Care in SastoMed GmbH, to which Sangui BioTech GmbH has licensed the worldwide distribution rights for the wound spray Granulox, sales agreements with numerous distribution partners have been terminated or not extended by SastoMed GmbH. These territories will in future be managed by Mölnlycke Health Care. Corresponding marketing operations have already been initiated so that - after successful integration - these areas will also generate significant revenues amounts.

Even after the acquisition of SastoMed GmbH by the Mölyncke Health Group, the Zuellig Group will be responsible for the Southeast Asian market and continue its successful work.

The penetration of the Southeast Asian market by the Zuellig Group is proceeding according to plan.

Granolox was approved in three additional countries (Indonesia, Malaysia and Taiwan) during the past quarter. In the meantime, the first market launch in Southeast Asia has taken place: In Thailand, the planned figures were significantly exceeded. Market launches for seven more countries are planned for the next nine months. The gratifying business in Southeast Asia will at least offset the temporary decline in revenues in other territories expected as a result of the acquisition by Mölnycke Health Care.

On July 5, 2018, the Sangui Know-How- und Patent Verwertungsgesellschaft mbH & Co. KG was entered in the commercial register of the Hamburg District Court. Sangui Know-How- und Patentverwertungsgesellschaft mbH & Co. KG will in future be responsible within the Sangui Group for the administration of the license agreement concluded with SastoMed GmbH. In this connection, Sangui Know-How- und Patentverwertungsgesellschaft mbH & Co. KG has acquired this license agreement from Sangui BioTech GmbH. Shareholders of Sangui Know-How- und Patentverwertungsgesellschaft mbH & Co. KG are Sangui BioTech GmbH as general partner with a share of 99.8% and SastoMed GmbH as the sole limited partner with a stake of 0.2%. The management is the responsibility of Sangui BioTech GmbH.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
Fax: +49 (2302) 915191
e-mail: [email protected]

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.



25.07.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this